S&P 500 Technology Sector SEC Filings — May 18, 2026

18-05-2026

Estrella Immunopharma reported a net loss of $2.29M for Q1 2026, an 8.9% increase from $2.10M in Q1 2025, driven largely by a 28.5% surge in G&A expenses. However, the company improved its stockholders' deficit from ($10.37M) to ($5.27M) through a $7.24M net registered direct offering and reduced total liabilities by $4.62M, primarily by paying down $4.13M in related party accrued liabilities. Cash increased 39% to $1.93M, but operating cash burn widened dramatically to $6.70M from $0.47M year-over-year, signaling heavy near-term cash consumption.

• · R&D expenses were approximately 61% of total operating expenses in Q1 2026, with $1.375M from related party (same as prior year).
• · G&A expenses increased 28.5% YoY to $891,789, partly due to stock-based compensation of $146,714 in Q1 2026 vs $159,095 in Q1 2025.
• · The company issued 4,063,290 shares of common stock, prefunded warrants, and common stock warrants in a registered direct offering, generating gross proceeds of $7,999,988 but incurring $758,882 in transaction costs.
• · Warrants outstanding surged from 2,214,993 to 10,178,928, with 8,594,935 new warrants granted at a weighted average exercise price of $1.23 (down from $11.50).
• · Aggregate intrinsic value of stock options fell from $2.682M to $0.882M, indicating a significant drop in the company's stock price.
• · Net cash used in operating activities was $6.70M, largely due to a $4.125M payment of related party accrued liabilities.
• · The company had no revenue and remains in the development stage with an accumulated deficit of $39.28M.

18-05-2026

Genco Shipping & Trading Ltd filed an amendment to its tender offer response (SC 14D9/A) reporting strong Q1 2026 financial results compared to a loss in Q1 2025. Net income swung to $9.3 million from a net loss of $11.9 million, and adjusted EBITDA surged over 350% to $36.2 million. However, daily vessel operating expenses rose 3.2% year-over-year, and the company recorded impairment charges of $0.5 million. The filing also reiterates management's solicitation of proxies for the 2026 Annual Meeting using a WHITE proxy card, amid an ongoing tender offer.

• · Net interest expense increased to $3.8M in Q1 2026 from $2.2M in Q1 2025.
• · Depreciation and amortization rose to $21.0M from $17.7M year-over-year.
• · Net gain on sale of vessels of $2.1M and other operating expense of $3.8M were recorded in Q1 2026 (none in Q1 2025).
• · Realized loss on fuel hedges of $40k in Q1 2026 vs a gain of $8k in Q1 2025.
• · The company provides estimated TCE for Q2 2026 (not quantified in filing) based on fixtures to date and FFA curve.
• · The filing is an amendment to a Schedule 14D-9, indicating an active tender offer; the company recommends shareholders vote the WHITE proxy card.

18-05-2026

ImmunityBio entered an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory for the Tokyo strain of BCG, aiming to address the chronic BCG shortage in the U.S. The agreement follows a positive Phase III readout (SWOG S1602) demonstrating non-inferior efficacy of the Tokyo strain versus TICE BCG in BCG-naïve high-grade NMIBC, with a hazard ratio of 0.82 (95.8% CI 0.63–1.08) against a non-inferiority margin of 1.34. ImmunityBio plans to engage the FDA to pursue U.S. approval and serve as the sole BLA applicant, while continuing its Expanded Access Program for recombinant BCG through its partnership with Serum Institute of India.

• · The Tokyo strain of BCG has been used in Japan for almost 30 years for high-risk NMIBC.
• · SWOG S1602 enrolled 1,000 patients (984 eligible) between February 2017 and December 2020, randomized 1:1:1 to TICE BCG (n=330), intravesical Tokyo-172 BCG (n=327), or intradermal priming + intravesical Tokyo-172 BCG (n=327).
• · Progression-free survival was similar across all arms.
• · The BCG shortage in the U.S. has persisted for over a decade.
• · ANKTIVA is FDA-approved in combination with BCG for BCG-unresponsive NMIBC with CIS; the Tokyo strain is investigational in the U.S.
• · The partnership gives ImmunityBio a second potential BCG source (the first being Serum Institute's rBCG).

18-05-2026

Yimutian Inc. (YMT) filed an amendment (20-F/A) to its annual report on May 18, 2026, containing boilerplate updates to its memorandum and articles of association regarding share transfer procedures, board authority to issue preferred shares without shareholder vote, and the ability to register by continuation in another jurisdiction. The filing provides no financial data, operational metrics, or material business developments.

18-05-2026

Cottonwood Communities, Inc. disclosed the issuance of 257,866 shares of its Series 2025 Preferred Stock between April 22 and May 17, 2026, raising $2,541,000 in net proceeds after commissions and fees. The offering, launched December 9, 2024, has a maximum of $150,000,000 and remains ongoing. As of May 17, 2026, 11,314,733 shares of Series 2025 Preferred Stock were outstanding.

• · Offering launched December 9, 2024, with a maximum of $150,000,000 in shares.
• · Purchase price is $10.00 per share with discounts available to certain categories of purchasers.
• · The offering is conducted under Rule 506(b) of Regulation D, exempt from registration, and limited to accredited investors without general solicitation.
• · Selling commissions of $117,060 and aggregate placement fees of $78,077 were paid in connection with the share sales.

18-05-2026

Snowflake Inc. filed definitive additional proxy materials (DEFA14A) with the SEC on May 18, 2026. The filing serves as a notice of supplemental solicitation document but contains no specific financial data or operational updates. The nature of the additional materials is not detailed in the filing-specific, indicating a routine procedural disclosure.

• · Filing type is DEFA14A (Definitive Additional Proxy Materials).
• · Filed on May 18, 2026.
• · No fee was required for this filing.

18-05-2026

BNY Mellon Strategic Municipals, Inc. filed a DEFA14A definitive additional proxy statement with the SEC on May 18, 2026. This filing supplements previously submitted proxy materials for shareholder consideration. No specific financial data or narrative content could be extracted from the provided filing text due to embedded image encoding.

18-05-2026

BNY Mellon Strategic Municipal Bond Fund, Inc. (DSM) filed a DEFA14A (additional proxy materials) on May 18, 2026. The filing consists solely of an image attachment with no textual financial or operational data, providing no new material information for investors.

18-05-2026

abrdn Palladium ETF Trust (PALL) executed a 5-for-1 forward stock split on May 18, 2026. Pre-split shares outstanding were 6,112,500 with a net asset value (NAV) of $128.69 per share; post-split shares increased to 30,562,500 with the NAV adjusted to $25.74 per share. The split does not change the total value of the trust, and the CUSIP number and ticker symbol (PALL) remain unchanged.

• · The forward split was announced in a press release issued on April 22, 2026.
• · The record date for the split was the close of markets on May 14, 2026.
• · The trust's CUSIP number and ticker symbol (PALL) were not affected by the split.

18-05-2026

Acadia Healthcare Company, Inc. disclosed on May 18, 2026 that a jury awarded $35 million in compensatory damages and $70 million in punitive damages (total $105 million) in an employment-related retaliatory termination lawsuit against its indirect subsidiary, Fashion Valley CTC. The company strongly disagrees with the verdict and intends to challenge it through post-trial motions and appeal. The outcome remains uncertain.

• · The lawsuit was filed by a former employee who was terminated in October 2023, alleging retaliatory termination.
• · The trial began in late April 2026 and the verdict was reached on May 12, 2026.
• · Acadia Healthcare Company, Inc. is not a party to the lawsuit; only its indirect subsidiary Fashion Valley CTC is the defendant.
• · Fashion Valley operates a comprehensive treatment center in San Diego County, California.
• · The company stated the award 'far exceeds any reasonable expectation based on precedent for comparable employment cases.'

18-05-2026

Madison Technologies Inc. reported no revenue for Q1 2026, with a net loss of $660,455, an improvement of 6.9% from $709,477 in Q1 2025. Operating expenses fell 26.8% to $86,353 and interest expense declined 3.0% to $574,102, while cash used in operations surged 117.7% to $197,432, fully funded by a loan from a principal shareholder. Total liabilities increased to $24.1 million and stockholders' deficiency worsened to ($24.0 million), with zero cash on hand.

• · No revenue reported for either quarter; zero cash on hand throughout.
• · Prepaid expenses decreased from $130,568 to $90,921 (down 30.3%).
• · Accounts payable and accrued liabilities increased from $3,898,315 to $3,979,715 (up 2.1%), while accrued interest rose $212,125 to $3,192,632.
• · Loan from principal shareholder increased $197,432 to $923,014, exactly matching the operating cash deficit.
• · Senior secured notes remained at $7,340,093 with no amortization in the period.
• · Weighted average shares outstanding increased by 75 million shares (4.7%) compared to the prior year period.
• · No income tax expense or interest paid in either quarter.

18-05-2026

Arkadios Wealth Advisors filed its quarterly 13F-HR for the period ending March 31, 2026, revealing a portfolio valued at approximately $6.13 billion. The largest equity positions include Amazon, Invesco QQQ Trust, and Vanguard Total Stock Market ETF. Notably, the firm held extensive put option positions on the QQQ ETF, suggesting a hedged or cautious outlook on large-cap tech.

• · The report contains significant put option positions on the Invesco QQQ Trust (QQQ), with numerous contracts totaling over 20,000 shares in notional value (estimated $11M+ in premiums based on reported values).
• · Largest single equity by market value is Amazon.com Inc at approximately $78.6M across multiple accounts and options.
• · The portfolio includes a notable allocation to fixed-income ETFs, such as SPDR Portfolio Aggregate Bond ETF ($4.15M) and SPDR Portfolio Intermediate Term Treasury ETF ($7.83M).
• · Holdings span REITs (Alexandria, CubeSmart, Camden), energy (Vanguard Energy ETF, Sempra), healthcare (Johnson & Johnson, Elevance Health, DexCom), and technology (Hewlett Packard Enterprise, Akamai, Seagate).
• · The filing includes shares attributed to both 'ARK Advisory' and firm-wide accounts, with some positions marked as SOLE ownership without a sub-advisor designation.

18-05-2026

RideNow Group, Inc. received conditional approval from Polaris Acceptance to increase its credit facility from $74.65 million to $108 million. The activation requires execution of amended agreements and proof of property insurance within 30 days, and is subject to no material adverse change. If conditions are not met, the facility remains at the original $74.65 million.

• · The increase requires an Amended and Restated Guaranty from six specific entities: RideNow Group, Inc., North County 355 Holdings,Inc., Georgetown 355 Holdings, Inc., Fun Center Holdings, Inc., CMG Powersports, Inc., and America’s Powersports, Inc.
• · Property insurance must cover the maximum aggregate credit facility ($108M) and evidence must be provided.
• · The condition deadline is 30 days from April 15, 2026 (the letter date), and any material adverse change could void the increase.
• · The credit facility is for inventory financing from Polaris Acceptance, a Wells Fargo entity.

18-05-2026